Elsevier

Clinical Therapeutics

Volume 26, Issue 9, September 2004, Pages 1470-1478
Clinical Therapeutics

Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic

https://doi.org/10.1016/j.clinthera.2004.09.002Get rights and content

Abstract

Objective:

The goal of this study was to investigate the complications and control of warfarin treatment in patients with nonvalvular atrial fibrillation (NVAF) newly referred to an outpatient anticoagulation clinic.

Methods:

This study included new patients with NVAF who were referred to an anticoagulation clinic for warfarin therapy over a recruitment period of 21 months. To reflect real-world clinical practice, patient selection for anticoagulation and patient management were left to the referring physicians, who were blinded to their patients' participation in the study. Patients were interviewed in person at the first clinic visit and then by telephone every 4 to 6 weeks. They were questioned about any bleeding or thromboembolic events.

Results:

A total of 402 patients were included (100% of all new referrals over 21 months). The mean (SD) age was 72.3 (10.3) years, and 224 (56%) patients were men. The mean (SD) international normalized ratio (INR) was 2.4 (0.31). Patients were followed up for a mean (SD) of 19 (8.1) months (range, 1.0–31.0 months). They spent a mean (SD) 66% (18.3) of time in the target range of INR (ie, 2.0–3.0). Annual event rates were 1.7% (95% CI, 0.4%–3.0%) for major bleeding, 16.6% (95% CI, 13.0%–20.2%) for minor bleeding, 1.2% (95% CI, 0.1%–2.3%) for ischemic stroke, and 0.3% (95% CI, 0.2%–0.8%) for transient ischemic attacks. There were no cases of hemorrhagic stroke or fatal bleeding. Variability of INR and number of medications were identified as risk factors for bleeding (P = 0.03 and P = 0.001, respectively). There was no significant association between age and bleeding.

Conclusions:

Based on this analysis, the risks of long-term oral anticoagulation therapy in an outpatient anticoagulation clinic appear to reflect the results of clinical trials. Rates of ischemic stroke, major bleeding, and anticoagulation control were comparable. There was no age-related risk of complications.

References (24)

  • LandefeldC.S. et al.

    Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy

    Am J Med

    (1989)
  • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized clinical trials

    Arch Intern Med

    (1994)
  • EzekowitzM.D. et al.

    Preventing stroke in patients with atrial fibrillation

    JAMA

    (1999)
  • AntaniM.R. et al.

    Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation

    J Gen Intern Med

    (1996)
  • WheeldonN.M. et al.

    Screening for atrial fibrillation in primary care

    Heart

    (1998)
  • Stroke prevention in atrial fibrillation study Final results

    Circulation

    (1991)
  • RosendaalF.R. et al.

    A method to determine the optimal intensity of oral anticoagulant therapy

    Thromb Haemost

    (1993)
  • LancasterT.R. et al.

    The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial

    Arch Intern Med

    (1991)
  • FihnS.D. et al.

    The risk for and severity of bleeding complications in elderly patients treated with warfarin

    Ann Intern Med

    (1996)
  • O'ReillyR.A. et al.

    Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans

    Clin Pharmacol Ther

    (1987)
  • CohenN. et al.

    Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission

    Stroke

    (2000)
  • KalraL. et al.

    Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness

    BMJ

    (2000)
  • Cited by (50)

    • Neurological complications of cardiovascular drugs

      2021, Handbook of Clinical Neurology
    • Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: A single centre, double-blind, randomised, non-inferiority trial

      2015, The Lancet Haematology
      Citation Excerpt :

      We also calculated the variance growth rate as an indicator of INR variability between tests (B1 method).15 To calculate the non-inferiority margin, we used data from previous prospective studies16–19 in patients with mixed indications for anticoagulation, with an INR target of 2–3, monitored and dosed by our anticoagulation management centre. On the basis of these studies, we used an expected 3% annual thromboembolism incidence and a non-inferiority margin of 2·5%.

    • Oral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

      2012, Chest
      Citation Excerpt :

      Rates of thromboembolism with UC were not reported except in two studies in which the event rates were 6.2% and 8.1% per patient-year. Similarly, retrospective and prospective cohort studies of care provided by an AMS reported rates of major hemorrhage or thrombosis ranging from 1.4% to 3.3% and 0.7% to 6.3% per patient-year of therapy, respectively.164,170,207–210 Three retrospective comparative studies using a before-and-after design of patients managed by UC or an AMS reported significant improvements in the outcomes of hemorrhage or thrombosis with AMS-directed care.211–213

    View all citing articles on Scopus
    View full text